Oxford Biomedica (LON:OXB) Shares Down 14.6% – Time to Sell?

Oxford Biomedica plc (LON:OXB)’s stock price dropped 14.6% during mid-day trading on Friday . The company traded as low as GBX 441.50 and last traded at GBX 505. Approximately 6,604,510 shares traded hands during trading, an increase of 638% from the average daily volume of 895,491 shares. The stock had previously closed at GBX 591.

Analyst Upgrades and Downgrades

OXB has been the subject of a number of recent research reports. Royal Bank Of Canada lowered their target price on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a research note on Wednesday, June 24th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Oxford Biomedica has a consensus rating of “Buy” and a consensus target price of GBX 669.85.

Oxford Biomedica Trading Down 14.6%

The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. The firm’s 50 day moving average price is GBX 604.33 and its 200 day moving average price is GBX 650.49. The stock has a market capitalization of £611.24 million, a P/E ratio of -18.76 and a beta of 1.12.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.